Skip to main content
No.1 Press Release Service in Korea
Search
Search
Login
Create Account
Services
Contact Us
News
Services
About Us
Contact Us
Korean
News
All News
News by Region
Korea
Overseas
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Services
Why Korea Newswire?
How We Distribute
Services & Pricing
Basic
Standard
Premium
Global
Translation
Press Release Network in Korea
Korean Language
About Us
News
Services
Contact Us
Search
Cancel
Search
Submit Press Release
Latest News
News by Region
Korea
World
News by Industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Health News Releases
Today April 18
08:00
INB Korea Ltd removes the bubble of the price on air sterilizer, cutting the price by 70% , NEW ‘UPPERVIOLET ODEO’ product is launched
INB Korea Ltd, the manufacturer of ‘viruskiller’, a K- air purifier and sterilizer product in Korea that exported 20 million dollar to 53 countries during the COVID19 outbreak, announced on the 17th o
April 17, 09:57
A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer
Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos a
April 17, 09:15
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clin
April 16, 11:40
KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Jean-Baptiste (JB) Agnus as Chief
April 12, 15:00
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply
April 09, 14:28
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Ferring today published its 2023 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2024%2F04%2FFerring-Pharmaceutic
April 09, 13:19
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53923546&newsitemid=20240408059362&lan=en-US&anchor=TSE%3A4502%2FNYSE%
April 09, 12:05
AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine
PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients
April 09, 11:30
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the p
April 04, 15:10
Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin
Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500000-square-foo
April 04, 14:35
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.conformation-x.com&esheet=53921384&newsitemid=20240403623298&lan=en-US&anchor=Conformation-X+Ther
April 03, 15:20
Merz Enters Asset Purchase Agreement With a US-Based Biotech Company
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the tra
April 02, 13:50
KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Of
March 29, 10:55
Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
PCI Pharma Services, (“PCI”) a leading global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report (https://cts.businesswi
March 28, 10:30
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Sharehold
March 27, 13:30
Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
Medisca, a global leader in personalized medicine and pharmaceutical supply chain solutions, proudly announces the opening of the Medisca MAZ Lab (https://cts.businesswire.com/ct/CT?id=smartlink&url=h
March 26, 11:50
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative techno
March 22, 11:00
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&newsitemid=20240319911372&lan=en-US&anchor=TSE%3A4502%2FNYSE%
March 21, 13:29
Merck Invests More than € 300 Million in New Life Science Production Site in Korea
Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life Science business sector in Asia-Pacific
March 19, 15:19
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on M
March 19, 14:55
Crown Bioscience Recognized Once Again as T+ Employer® for the Third Year in a Row
Crown Bioscience (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.crownbio.com%2F&esheet=53911141&newsitemid=20240318198586&lan=en-US&anchor=Crown+Bioscience&index=1&md5=2736454e
March 17, 09:55
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monoth
March 15, 09:45
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global
March 14, 11:20
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product's status
March 14, 10:04
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53909424&newsitemid=20240313160788&lan=en-US&anchor=Takeda&index=1&md5=6f3040795d635d91a3047b63610ac3
March 13, 11:40
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnersh
March 12, 13:45
Nine Hospitals from Aster DM Healthcare Recognized in Newsweek’s ‘World’s Best Hospitals 2024’ List
Aster DM Healthcare (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.asterdmhealthcare.com%2F&esheet=53907936&newsitemid=20240311202772&lan=en-US&anchor=Aster+DM+Healthcare&index
March 12, 09:24
BIO KOREA 2024 Opens Registration for Business Partnering
BIO KOREA 2024 (https://www.biokorea.org/index.asp), jointly held by the Korea Health Industry Development Institute (https://www.khidi.or.kr/kps) (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do
March 11, 09:15
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1]
March 10, 13:55
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurologic
March 08, 09:40
Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the
March 07, 14:30
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
C₂N Diagnostics, LLC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.c2n.com&esheet=53905942&newsitemid=20240306427979&lan=en-US&anchor=C%26%238322%3BN+Diagnostics%2C+LLC&index=1
March 06, 10:30
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
March 03, 15:05
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV
The DRIPBaR (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fthedripbar.com%2F&esheet=53903816&newsitemid=20240301173923&lan=en-US&anchor=The+DRIPBaR&index=1&md5=5d9842f73fed8bbd9a42
March 03, 12:08
Technology Holdings Launches TH Healthcare & Life Sciences: Revolutionizing the Healthcare Investment Banking Landscape, leveraging over two decades of Healthcare Investment Banking transaction experience
Technology Holdings (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftechnologyholdings.com%2F&esheet=53901632&newsitemid=20240226928319&lan=en-US&anchor=Technology+Holdings&index=1&
February 29, 15:36
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
Galderma: Delivered against full year guidance for another consecutive year with strong financial performance · Galderma achieved net sales of 4.082 B USD, up 8.5% year-on-year on a constant cur
February 29, 15:25
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53901571&newsitemid=20240226565897&lan=en-US&anchor=Takeda&index=1&md5=66a3b376ad586d49f3651a4e8ba4fd
February 29, 14:00
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2F&esheet=53892194&newsitemid=20240206439222&lan=en-US&anchor=Medidata&index=1&md5=ba87686335d43b4ad5753838
February 28, 17:02
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, h
February 28, 12:05
ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at P
February 28, 11:50
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53900859&newsitemid=20240226047170&lan=en-US&anchor=BeiGene&index=1&md5=9fa7f0cbddab2bafa454d24c749
February 25, 10:15
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Celltrion today presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) in patients with moderately to severely active Crohn’s disease (CD) and ulcerative c
February 23, 17:35
New Swiss Made Features for Cataract Surgery Lens Selection
The company Swiss Advanced Vision (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fsav-iol.com%2F&esheet=53899982&newsitemid=20240222791326&lan=en-US&anchor=Swiss+Advanced+Vision&ind
February 23, 14:10
ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emer
February 22, 17:20
Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance
Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=53898438&newsitemid=20240221815046&lan=en-US&anchor=Parse+Biosciences&index=1&md
February 22, 15:35
MMI Raises $110 Million in Series C Financing
MMI (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.mmimicro.com%2F&esheet=53897487&newsitemid=20240221774903&lan=en-US&anchor=MMI&index=1&md5=d18846e1e7a7c30d597fb199c3bb2d60)
February 21, 17:25
Sinovac Amends Shareholder Rights Plan
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder righ
February 21, 13:45
AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Singaporean regulatory review an
February 21, 09:30
MRM Health Initiates Clinical Research in Parkinson’s Disease
MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study
February 20, 10:10
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences, Inc. The agreement provides Gilead access t
1
2
3
4
5
»
50 per page
25 per page
50 per page
75 per page
100 per page
Distribute Your News to
KOREA
The largest press release distribution network in Korea
34,000 journalists
7,000 media outlets
345 industry channel
80,000 subscribers
Get Started
Global PR service
Reach Your Target
Audience in 160 Countries
powered by
Get Started
News by region
Korea
Overseas
News by industry
Health
Economy
Education
Finance
Technology
Life Style
Leisure
Culture & Entertainment
Transportation
Society
Heavy Industries
Environment
Government
Notice